Qize Ding's questions to Genmab A/S (GMAB) leadership • Q2 2025
Question
Qize Ding from Redburn Atlantic asked for more detail on the planned RINA S trial in non-small cell lung cancer, specifically the line of therapy and whether it would be tested as a monotherapy or in combination.
Answer
Citing the competitive landscape, Chief Medical Officer Tahamtan Ahmadi declined to provide specific details but confirmed the study is designed to explore RINA S as both a monotherapy and in combination therapy. He suggested the company's past development strategies offer a clue to the approach.